Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats

[1]  F. Leenen,et al.  Prevention of Salt-induced Hypertension and Fibrosis by AT1-receptor Blockers in Dahl S Rats , 2008, Journal of cardiovascular pharmacology.

[2]  N. Kobayashi,et al.  Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. , 2008, American journal of hypertension.

[3]  K. Sunagawa,et al.  Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. , 2006, Cardiovascular research.

[4]  S. Mochizuki,et al.  Combined treatment with valsartan and spironolactone prevents cardiovascular remodeling in renovascular hypertensive rats. , 2006, International heart journal.

[5]  S. Mochizuki,et al.  Effects of bradykinin on cardiovascular remodeling in renovascular hypertensive rats. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[6]  S. Mochizuki,et al.  Cardioprotective Action of Perindopril versus Candesartan in Renovascular Hypertensive Rats , 2004, Cardiovascular Drugs and Therapy.

[7]  Mitchell A. Avery,et al.  Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating Activity , 2004, Hypertension.

[8]  K. Tsuchiya,et al.  Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats , 2004, Journal of hypertension.

[9]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[10]  E. Frohlich,et al.  Local cardiac renin-angiotensin system: hypertension and cardiac failure. , 2002, Journal of molecular and cellular cardiology.

[11]  K. Tsuchiya,et al.  Aldosterone Breakthrough During Angiotensin II Receptor Antagonist Therapy in Stroke-Prone Spontaneously Hypertensive Rats , 2002, Hypertension.

[12]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[13]  M. Ohishi,et al.  Perindopril Alters Vascular Angiotensin-Converting Enzyme, AT1 Receptor, and Nitric Oxide Synthase Expression in Patients With Coronary Heart Disease , 2002, Hypertension.

[14]  R. Fagard,et al.  Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors , 2001, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[15]  J. Croft,et al.  Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. , 2000, American heart journal.

[16]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[17]  S. Yusuf,et al.  Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. , 1999, Circulation.

[18]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[19]  K. Weber,et al.  Extra-adrenal mineralocorticoids and cardiovascular tissue. , 1999, Journal of molecular and cellular cardiology.

[20]  C. Delcayre,et al.  Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. , 1999, Hypertension.

[21]  IsseiKomuro,et al.  Pressure Overload Induces Cardiac Hypertrophy in Angiotensin II Type 1A Receptor Knockout Mice , 1998 .

[22]  M. Okoshi,et al.  Myocardial fibrosis rather than hypertrophy induces diastolic dysfunction in renovascular hypertensive rats. , 1997, Canadian journal of physiology and pharmacology.

[23]  M. Yano,et al.  Dose-dependent effect of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy. , 1997, American journal of physiology. Heart and circulatory physiology.

[24]  P. Okin,et al.  Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials , 1996, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[25]  C. Delcayre,et al.  Biological determinants of aldosterone-induced cardiac fibrosis in rats. , 1995, Hypertension.

[26]  J. Bertram,et al.  Cardiovascular hypertrophy in one‐kidney, one clip renal hypertensive rats: a role for angiotensin II? , 1994, Journal of hypertension.

[27]  G. Gibbons,et al.  The emerging concept of vascular remodeling. , 1994, The New England journal of medicine.

[28]  H. Sasamura,et al.  Effects of angiotensin II, ACTH, and KCl on the adrenal renin-angiotensin system in the rat. , 1990, Acta endocrinologica.

[29]  T. Takishima,et al.  Coronary dilator reserve and morphological changes after relief of pressure-overload in rats. , 1993, Journal of molecular and cellular cardiology.